The main treatment options for patients suffering from epilepsy, a chronic disorder of the brain that affects 40–70 of every 100 000 people in the developed world,1 are antiepileptic drugs (AEDs), surgical treatment or vagus nerve stimulation. The treatment option chosen depends on the type and severity of the disorder. More than 15 AEDs have been approved for the treatment of epilepsy in North America and Europe.2 Patients may have to try several medications before they can control their seizures: ≤ 50%, achieve control after trying 1 medication; another 10% achieve control after 2, and a further 5% after 3 or 4 medications.3 If medications cannot control the seizures, surgical treatments are considered.3 However, despite successful surgical treatment, most patients remain on AEDs.

Abstract

Objective: Long-term use of phenytoin (PHT) causes gingival hyperplasia; however, little is known about the oral side effects of other antiepileptic drugs (AEDs). Through a systematic review of the literature, we explored the effects of AEDs on the oral health of patients with epilepsy.

Methods: We searched PubMed, EMBASE and the Cochrane library between January 1963 and August 2010. The search strategy retrieved 170 abstracts. We included studies that involved original research and had ≥ 10 patients in our review. We also checked the reference lists of reviews, letters and other manuscripts to find studies that met our selection criteria.

Results: Only 15 articles were included in the final analysis. Gingival hyperplasia was very common in patients taking PHT (16%–94% of patients). Alveolar bone loss occurred in patients taking carbamazepine or PHT. Patients taking valproate, carbamazepine or phenobarbital also had gingival hyperplasia. We found no published studies of newer-generation AEDs.

Conclusion: Although several studies examined the effects of PHT on oral health, none have studied those of the newer generation of AEDs. Studies exploring oral side effects of AEDs are needed.
Among the many social and systemic challenges patients with epilepsy face is the deterioration of their oral health. Their use of AEDs is associated with the initiation and progression of gingival hyperplasia (GH). Phenytoin (PHT), the most common drug chosen to treat epileptic seizures, has a range of adverse effects, from blurred vision and skin rashes to muscle pain, to GH. In 1939, Kimball was first to report PHT-induced GH. Currently, patients experiencing adverse side effects while taking PHT may be prescribed newer-generation AEDs. Because few studies of their adverse effects on a patient’s oral health have been done, little is known about the side effects of these newer drugs. Consequently, we systematically reviewed the published literature to explore the effects of all AEDs on oral health.

**Methods**

**Search Strategy and Data Sources**

We reviewed the literature published between January 1963 and August 2010 using MEDLINE (after 1963), EMBASE and the Cochrane Library. We also searched the bibliographies of pertinent original articles, narrative reviews, abstracts and book chapters. We included articles published in all languages. With the help of a reference librarian at the London Health Sciences Centre, we adapted this PubMed search strategy to search these databases: Anticonvulsants [mh] AND epilepsy [mh] AND (mouth diseases [mh] OR oral health [mh] OR dental care [mh] OR dentistry [mh]).

**Study Selection and Analysis**

For our review, we selected retrospective or prospective cohort studies that included patients with all types of epilepsy taking AEDs, as well as case series of ≥ 10 cases. Also eligible for inclusion were descriptive and comparative studies, systematic reviews and meta-analyses. We excluded narrative (nonsystematic) reviews, editorials, abstracts, letters to the editor and case reports, as well as duplicate publications, namely, those involving the same population in different reports.

Two authors (CEA, JGB) independently applied the inclusion criteria to the articles retrieved. A third investigator (ALPC) adjudicated disagreements.

From each study reviewed, we obtained the following information: the type and design of the study, the number of subjects, the type of antiepileptic drugs used, outcomes measured, oral and dental findings and percentage or number of patients affected.

Analysis of the data obtained was mainly descriptive.

**Results**

Of the 170 articles identified with our search strategy, 15 fit the selection criteria for inclusion in our study (Fig. 1). The methodological design of all studies included in our literature review was either cross-sectional, retrospective or prospective-cohort. The mean number of patients included in these studies was 127 (range 23–454 patients). The AEDs assessed were PHT, carbamazepine (CBZ), phenobarbital (Pb) and valproate (VPA).

The oral health of patients undergoing treatment with AEDs was measured with all or some of the following methods in the studies reviewed:
<table>
<thead>
<tr>
<th>Study</th>
<th>Type of study</th>
<th>No. of patients</th>
<th>AED</th>
<th>Outcome measured</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Klar (1973)</td>
<td>Cross-sectional</td>
<td>312</td>
<td>PHT</td>
<td>GH</td>
<td>64% of patients affected</td>
</tr>
<tr>
<td>Seymour et al. (1985)</td>
<td>Cross-sectional</td>
<td>30</td>
<td>PHT vs VPA</td>
<td>GH</td>
<td>PHT &gt; VPA = control</td>
</tr>
<tr>
<td>Delasnerie-Laupretre and Turpin (1991)</td>
<td>Retrospective cohort</td>
<td>454</td>
<td>Pb</td>
<td>GH</td>
<td>1% of patients affected</td>
</tr>
<tr>
<td>Thomason et al. (1992)</td>
<td>Cross-sectional</td>
<td>23</td>
<td>PHT vs control</td>
<td>GH</td>
<td>&gt; gingival overgrowth in patients on PHT</td>
</tr>
<tr>
<td>Dahllöf et al. (1993)</td>
<td>Cross-sectional</td>
<td>40</td>
<td>PHT vs CBZ</td>
<td>GH + alveolar bone loss</td>
<td>GH: 35% of patients on PHT, 10% on CBZ Alveolar bone loss: 70% of patients on PHT, 75% on CBZ</td>
</tr>
<tr>
<td>Perlik et al. (1995)</td>
<td>Cross-sectional</td>
<td>54</td>
<td>PHT vs PHT + old generation AEDs</td>
<td>GH</td>
<td>61% of patients affected Men &gt; women No correlation with PHT dose</td>
</tr>
<tr>
<td>Galas-Zgorzalewicz et al. (1996)</td>
<td>Prospective cohort</td>
<td>63</td>
<td>CBZ, VPA, PHT</td>
<td>GH</td>
<td>30% of patients affected</td>
</tr>
<tr>
<td>Ball et al. (1996)</td>
<td>Cross-sectional</td>
<td>36</td>
<td>PHT vs PHT + CBZ vs PHT + VPA</td>
<td>GH</td>
<td>47% of patients affected</td>
</tr>
<tr>
<td>Sasaki and Maita (1998)</td>
<td>Cross-sectional</td>
<td>36</td>
<td>PHT vs control</td>
<td>GH</td>
<td>94% of patients affect No correlation with PHT dosage levels</td>
</tr>
<tr>
<td>Trevisol-Bittencourt et al. (1999)</td>
<td>Prospective cohort</td>
<td>61</td>
<td>PHT</td>
<td>GH</td>
<td>52% of patients affected GH combined with acne &amp; hirsutism</td>
</tr>
<tr>
<td>Brunet et al. (2001)</td>
<td>Cross-sectional</td>
<td>157</td>
<td>PHT vs non-PHT vs control</td>
<td>GH</td>
<td>16% of patients on PHT, 4% on non-PHT Higher odds to develop if taking PHT</td>
</tr>
<tr>
<td>Prasad et al. (2002)</td>
<td>Prospective cohort</td>
<td>30</td>
<td>PHT</td>
<td>GH</td>
<td>57% of patients affected</td>
</tr>
<tr>
<td>Tan et al. (2004)</td>
<td>Cross-sectional</td>
<td>118</td>
<td>VPA vs non-VPA (CBZ, Pb) vs control</td>
<td>GH</td>
<td>% not stated Higher odds to develop GH on AEDs</td>
</tr>
<tr>
<td>Prasad et al. (2004)</td>
<td>Prospective cohort</td>
<td>51</td>
<td>PHT</td>
<td>GH</td>
<td>55% of patients affected</td>
</tr>
<tr>
<td>Gurbuz and Tan (2010)</td>
<td>Cross-sectional</td>
<td>442</td>
<td>CBZ, VPA, Pb</td>
<td>GH</td>
<td>0% of patients on CBZ; 42% on VPA; 16% on Pb</td>
</tr>
</tbody>
</table>

AED = antiepileptic drug, CBZ = carbamazepine, GH = gingival overgrowth, Pb = phenobarbital, PHT = phenytoin, VPA = valproate
The gingival index, which assesses the colour of the gingiva; and the presence of edema, bleeding on palpation or spontaneous bleeding, inflammation and ulcerations.  

The plaque index, which assesses the presence of plaque in the gingiva, teeth and gingival pockets.  

Assessment of probing depth, which measures gingival pockets at different areas around each tooth.  

Assessment of gingival enlargement, which determines gingival overgrowth based on different standardized indexes validated in the dental literature.  

Survey of oral hygiene habits, which assesses the frequency of tooth brushing and flossing.

**Studies of PHT**

Of the 15 studies we reviewed, 12 studies assessed the effects of PHT. Eleven of these 12 studies included patients on monotherapy with PHT; 2 of the 12 included patients using polytherapy with PHT and ≥ 1 other AED (Table 1). Eight of these 12 studies were cross-sectional studies; the other 4 were prospective cohort studies. In all 12 studies, the use of PHT was associated with the development of GH. Ten of these studies identified the percentage of patients taking PHT who developed GH (16%–94%) (Fig. 2), one of which found that 70% of its patients taking PHT also had alveolar bone loss. The remaining studies focused on risk factors for the development of GH and did not provide the percentage of patients affected with GH.

Increasing dose and duration of drug intake tended to result in greater severity of GH. Results of studies that examined the correlation between the dosage of PHT and the duration and severity of GH were contradictory: some studies supported the correlation; others refuted it.

Further, 1 study found that more men than women had GH.

**Studies of Other AEDs**

The 5 studies that assessed the effects of VPA focused on the development of GH. Four of these studies used a cross-sectional design and 1 study, a prospective-cohort design. Only 3 studies assessed VPA as monotherapy, of which did not provide the number of patients affected with GH, but found lower odds for developing GH with VPA than with PHT.
monotherapy. One study\textsuperscript{25} found GH in 42\% of patients taking VPA monotherapy.

Five studies\textsuperscript{15,17,18,23,25} focused on CBZ. In its assessment of the relationship between the intake of CBZ and the development of GH, 1 study\textsuperscript{15} found that 10\% of patients taking CBZ developed GH. In this same study, alveolar bone loss occurred in 75\% of patients taking CBZ. In the remaining studies,\textsuperscript{17,18,23,25} patients received polytherapy with some combination of PHT, CBZ, Pb or VPA. One recent study\textsuperscript{25} found no evidence of GH in patients taking CBZ.

Finally, in the 3 studies\textsuperscript{13,23,25} that assessed the oral health of patients taking Pb, GH occurred in 1\%–16\% of patients.

Studies of Newer-Generation AEDs

We found no studies that assessed the oral health of patients taking newer-generation AEDs.

Discussion

From our review of the literature about the effects of all types of AEDs on the oral health of patients with epileptic seizures, we found that the most common oral side effect of AEDs was GH.

GH is characterized by the overgrowth of gingival subepithelial connective tissue and epithelium that develops about 1–3 months after the start of PHT treatment. This tissue enlargement typically begins at the interdental papilla and encroaches on the crowns of all teeth. Gingival overgrowth is not painful; however, gingival tissues that are traumatized during mastication, for example, may become tender. GH also creates conditions that allow plaque to accumulate easily, which increases bleeding in the dental sulcus and interdental papillary tissues. These factors make it much more difficult for patients to practise proper oral hygiene, resulting in the deterioration of their oral health. If left untreated, GH can shift the patient’s dentition or cover the entire crown of the affected teeth.\textsuperscript{9–28}

After numerous studies of the incidence of GH in different populations treated with PHT,\textsuperscript{11,12,14–22,24} it is widely accepted that patients treated with PHT may experience GH. More recently, research has focused on understanding the interrelationship between plaque, treatment dosage and duration, and the adverse effects of PHT.\textsuperscript{23–25,29–31} Almost all aspects of the oral and dental health status of patients with epilepsy treated with AEDs had significantly poorer oral health if they used PHT.\textsuperscript{11–25}

The pathogenesis of PHT-induced GH has also been the focus of much research. PHT is largely eliminated by the hepatic system; the major metabolite formed is 5-(4-hydroxyphenyl)-5-phenylhydantoin (4-HPPH). Kamali and colleagues\textsuperscript{26} found that high serum concentrations of 4-HPPH were linked to the production of gingival overgrowth in cats and rats. A high plasma concentration of PHT or 4-HPPH may be an important factor in the observed interspecies differences in the development of GH. However, further investigation is needed.

In a controlled trial that examined the relationship among CYP2C polymorphisms, PHT metabolism and gingival overgrowth in people with epilepsy, Soga and colleagues\textsuperscript{29} found that CYP2C9 carriers can be used to predict serum concentration from daily PHT use. This finding could help predict the possible development and severity of GH.

It is generally accepted that AEDs have side effects that diminish the patient’s oral health; however when the drugs are used short-term, such effects can be reversed once treatment has ceased.\textsuperscript{27} For patients taking AEDs for prolonged periods of time, good oral hygiene may be crucial to their ability to control the severity of GH. The role of the oral health care professionals is critical in reducing the severity and extent of GH in patients on short-term or prolonged AED therapy. Patients need to attend educational sessions and prevention programs to motivate them to use proper oral hygiene, in addition to their regular visits to the dentist or dental hygienist. Such action should considerably diminish the side effects of AEDs therapy, such as GH.

Although patients with epilepsy have a higher rate of dental caries, AEDs may increase their risk of caries.\textsuperscript{32} Moreover, the number of decayed and missing teeth, and the degree of abrasion and higher periodontal indexes they have is much worse than that of the general population. They also have far fewer restored and replaced teeth.\textsuperscript{30,31} If these patients do not visit a dentist or a dental clinic on a regular basis,\textsuperscript{25,33} it is essential that dentists know the exact side effects related to all
AEDs, particularly those belonging to the newer-generation AEDs because they are prescribed more often.

Although the literature about the association of GH with PHT is extensive, information about the effects of newer-generation AEDs on oral health is profoundly lacking. The lack of recent published literature (≤ 5 years) limits the conclusions of this systematic review. Prospective, controlled studies are needed. Identifying the types and frequency of adverse events caused by AEDs is critical to establishing policies to prevent these events and decrease harm.

THE AUTHORS

Ms. Cornacchio is currently a 4th-year dental student at the Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario.

Dr. Burneo is associate professor of neurology, biostatistics and epidemiology at the Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario; and co-director of the epilepsy program, University of Western Ontario, London Health Sciences Centre, London, Ontario.

Dr. Aragon is staff member at the dental department at the London Health Science Centre and maintains a full-time private practice limited to prosthodontics in London, Ontario. At the time this study was done, she was assistant professor in the division of restorative dentistry at the Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario.

Acknowledgements: We thank the London Health Sciences Library for their help with the literature search. We acknowledge professional help received in the preparation of the manuscript.

Correspondence to: Dr. Cecilia E. Aragon, Aragon Prosthodontics, 203-1135 Adelaide Street North, London, ON NSY 5K7. Email: doctor@aragonprosthodontics.com

Dr. Burneo has received financial support for research and compensation for serving on the advisory board committee of UCB Canada Inc. Dr. Aragon and Ms. Cornacchio have no declared financial interests.

This article has been peer reviewed.

References


